The company concluded KENGREAL is a P2Y12
platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12
platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Several platelet function assays are available, including light transmission aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and the point-of-care VerifyNow P2Y12
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12
Clopidogrel, a P2Y12
platelet inhibitor, is approved for the treatment of acute coronary syndrome and for patients who have had a recent MI, recent stroke, or established peripheral artery disease.
Clopidogrel, a P2Y12
platelet inhibitor taken orally once a day, is approved for the treatment of acute coronary syndrome and for patients who have had a recent myocardial infarction, recent stroke, or established peripheral artery disease.
[USPRwire, Wed Apr 03 2019] Dual antiplatelet therapy is defined as the use of aspirin and P2Y12
receptor inhibitor to prevent blood clotting, and through a double mechanism, it prevents thrombotic complications.
To the Editor: Current treatment guidelines for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) recommend dual antiplatelet therapy, a combination of aspirin and a P2Y12
inhibitor (i.e., clopidogrel, prasugrel, and ticagrelor) for a minimum of 12 months.
In addition, patients in the CS group used P2Y12
receptor inhibitor of platelet (P2Y12
inhibitors) more frequently than those in the non-CS group (P = 0.04).
Medicines Company (NASDAQ:MDCO), a pharmaceutical company focused on the treatment of critical care patients, has received approval from the US Food and Drug Administration for its Kengreal (cangrelor) as an adjunctive therapy to percutaneous coronary intervention for decreasing periprocedural thrombotic events in patients who have not been treated with a P2Y12
inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor, it was reported on Tuesday.
By targeting the secondary wave of platelet recruitment with P2Y12
antagonists and/or COX-1 inhibitors, an antithrombotic effect is achieved, with reduced risk of bleeding in comparison to other antithrombotic therapies that target biologically active clotting factors, such as warfarin.
Price, director of the cardiac catheterization laboratory at the Scripps Clinic, La Jolla, Calif., presented the findings of the Genotype Information and Functional Testing Exome (GIFT EXOME) study, in which he and his coworkers performed whole exome analysis on genetic material obtained from 192 self-identified white participants in the earlier GRAVITAS (Gauging Responsiveness With a VerifyNow P2Y12
Assay - Impact on Thrombosis and Safety) trial, That study, for which Dr.